Logo image of MTNB

MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Fundamental Analysis

NYSEARCA:MTNB - NYSE Arca - US5768103039 - Common Stock - Currency: USD

0.64  +0.06 (+9.97%)

After market: 0.64 0 (0%)

Fundamental Rating

2

Taking everything into account, MTNB scores 2 out of 10 in our fundamental rating. MTNB was compared to 572 industry peers in the Biotechnology industry. While MTNB seems to be doing ok healthwise, there are quite some concerns on its profitability. MTNB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTNB had negative earnings in the past year.
MTNB had a negative operating cash flow in the past year.
MTNB had negative earnings in each of the past 5 years.
In the past 5 years MTNB always reported negative operating cash flow.
MTNB Yearly Net Income VS EBIT VS OCF VS FCFMTNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

MTNB has a worse Return On Assets (-102.70%) than 76.91% of its industry peers.
Looking at the Return On Equity, with a value of -133.92%, MTNB is doing worse than 62.70% of the companies in the same industry.
Industry RankSector Rank
ROA -102.7%
ROE -133.92%
ROIC N/A
ROA(3y)-58.95%
ROA(5y)-51.01%
ROE(3y)-73.87%
ROE(5y)-62.69%
ROIC(3y)N/A
ROIC(5y)N/A
MTNB Yearly ROA, ROE, ROICMTNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTNB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTNB Yearly Profit, Operating, Gross MarginsMTNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
MTNB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, MTNB has less shares outstanding
MTNB has a worse debt/assets ratio than last year.
MTNB Yearly Shares OutstandingMTNB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
MTNB Yearly Total Debt VS Total AssetsMTNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -15.58, we must say that MTNB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -15.58, MTNB is doing worse than 83.13% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that MTNB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, MTNB perfoms like the industry average, outperforming 47.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.58
ROIC/WACCN/A
WACC9.43%
MTNB Yearly LT Debt VS Equity VS FCFMTNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 5.53 indicates that MTNB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.53, MTNB is in line with its industry, outperforming 58.44% of the companies in the same industry.
MTNB has a Quick Ratio of 5.53. This indicates that MTNB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MTNB (5.53) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.53
Quick Ratio 5.53
MTNB Yearly Current Assets VS Current LiabilitesMTNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

MTNB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.91%, which is quite impressive.
Looking at the last year, MTNB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
MTNB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.71% yearly.
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
Revenue 1Y (TTM)-100%
Revenue growth 3Y90.58%
Revenue growth 5Y55.71%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 45.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, MTNB will show a very strong growth in Revenue. The Revenue will grow by 155.73% on average per year.
EPS Next Y20.63%
EPS Next 2Y20.15%
EPS Next 3Y2.37%
EPS Next 5Y45.6%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y155.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MTNB Yearly Revenue VS EstimatesMTNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
MTNB Yearly EPS VS EstimatesMTNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTNB Price Earnings VS Forward Price EarningsMTNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTNB Per share dataMTNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.15%
EPS Next 3Y2.37%

More info and screens

0

5. Dividend

5.1 Amount

MTNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (2/21/2025, 8:04:00 PM)

After market: 0.64 0 (0%)

0.64

+0.06 (+9.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-25 2025-03-25/amc
Inst Owners6.87%
Inst Owner Change-91.5%
Ins Owners0.94%
Ins Owner Change0%
Market Cap3.26M
Analysts45.71
Price Target30.6 (4681.25%)
Short Float %6.33%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.29%
Min EPS beat(2)21.01%
Max EPS beat(2)21.57%
EPS beat(4)4
Avg EPS beat(4)19.8%
Min EPS beat(4)1.96%
Max EPS beat(4)34.64%
EPS beat(8)8
Avg EPS beat(8)13.94%
EPS beat(12)11
Avg EPS beat(12)9.13%
EPS beat(16)13
Avg EPS beat(16)6.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2866.67%
EPS NY rev (1m)4.89%
EPS NY rev (3m)4.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-4.35
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0
BVpS3.1
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.7%
ROE -133.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.95%
ROA(5y)-51.01%
ROE(3y)-73.87%
ROE(5y)-62.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.53
Quick Ratio 5.53
Altman-Z -15.58
F-Score1
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)132.99%
Cap/Depr(5y)104.87%
Cap/Sales(3y)276.36%
Cap/Sales(5y)256.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
EPS Next Y20.63%
EPS Next 2Y20.15%
EPS Next 3Y2.37%
EPS Next 5Y45.6%
Revenue 1Y (TTM)-100%
Revenue growth 3Y90.58%
Revenue growth 5Y55.71%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y155.73%
EBIT growth 1Y5.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.05%
EBIT Next 3Y30.21%
EBIT Next 5YN/A
FCF growth 1Y13.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.89%
OCF growth 3YN/A
OCF growth 5YN/A